Biofilms pose a significant challenge in medical settings, leading to persistent infections. Phage therapy shows promise in biofilm eradication, but its effectiveness under dynamic flow conditions remains unclear.
Methods:
We used two novel phages isolated on Klebsiella, Llofrudd and Samara, and characterized their genomes, host range, virulence, and impact on biofilms. In this study, we built a simple catheterized bladder model with flow to investigate the impact of phage treatment on biofilm viability in a flow-based catheter model.
Results:
Our analyses demonstrate that phages Llofrudd and Samara are the same species and infect a limited number of strains (3/221), but crucially across three species: Klebsiella aerogenes, Klebsiella pneumoniae, and E. coli.
Conclusions:
Phage treatment significantly reduced E. coli biofilm viability in catheters both in static conditions and under flow and liberated bacteria from the biofilms, highlighting the potential of phage therapy as an intervention strategy for catheter-associated urinary tract infections (CAUTI).
FeneleyRC, HopleyIB, WellsPN. Urinary catheters: History, current status, adverse events and research agenda. J Med Eng Technol, 2015; 39(8):459–470; doi: 10.3109/03091902.2015.1085600
3.
ZarbP, CoignardB, GriskevicieneJ, et al.; Hospital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill, 2012; 17(46):20316.
4.
JacobsenSM, SticklerDJ, MobleyHL, et al.Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev, 2008; 21(1):26–59; doi: 10.1128/cmr.00019-07
5.
GreenMS, RubinsteinE, AmitP. Estimating the effects of nosocomial infections on the length of hospitalization. J Infect Dis, 1982; 145(5):667–672; doi: 10.1093/infdis/145.2.667
6.
HollenbeakCS, SchillingAL. The attributable cost of catheter-associated urinary tract infections in the United States: A systematic review. Am J Infect Control, 2018; 46(7):751–757; doi: 10.1016/j.ajic.2018.01.015
HallSJ, HarrisonS, HardingC, et al.British association of urological surgeons suprapubic catheter practice guidelines–revised. BJU Int, 2020; 126(4):416–422; doi: 10.1111/j.1464-410x.2011.10303_2.x
9.
ClaytonJL. Indwelling urinary catheters: A pathway to health care–associated infections. Aorn J, 2017; 105(5):446–452; doi: 10.1016/j.aorn.2017.02.013
10.
CorteseYJ, WagnerVE, TierneyM, et al.Review of catheter-associated urinary tract infections and in vitro urinary tract models. J Healthc Eng, 2018; 2018:2986742; doi: 10.1155/2018/2986742
11.
Al-HazmiH. Role of duration of catheterization and length of hospital stay on the rate of catheter-related hospital-acquired urinary tract infections. Res Rep Urol, 2015; 7:41–47; doi: 10.2147/rru.s75419
12.
O’neillJ. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist, 2014.
13.
MurrayCJL, IkutaKS, ShararaF, et al.Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 2022; 399(10325):629–655; doi: 10.1016/j.eururo.2022.08.023
14.
. Centers for Disease Control and Prevention. COVID-19: US impact on antimicrobial resistance, special report 2022. Atlanta GA US Dep Health Hum Serv Cent Dis Control Prev, 2022.
15.
GulA, KhanM, AliM, et al.Catheter associated urinary tract infection: Characterization of bacterial pathogens and their antimicrobial susceptibility pattern at two major tertiary care hospitals. Int J Pathol, 2021; 194–199.
16.
TacconelliE, MagriniN, KahlmeterG, et al.Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organ, 2017; 27.
17.
TacconelliE, CarraraE, SavoldiA, et al.; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis, 2018; 18(3):318–327; doi: 10.1016/s1473-3099(17)30753-3
18.
WazaitH, PatelH, VeerV, et al.Catheter‐associated urinary tract infections: Prevalence of uropathogens and pattern of antimicrobial resistance in a UK hospital (1996–2001). BJU Int, 2003; 91(9):806–809; doi: 10.1046/j.1464-410x.2003.04239.x
19.
HidronAI, EdwardsJR, PatelJ, et al.; Participating National Healthcare Safety Network Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol, 2008; 29(11):996–1011; doi: 10.1086/591861
20.
SabirN, IkramA, ZamanG, et al.Bacterial biofilm-based catheter-associated urinary tract infections: Causative pathogens and antibiotic resistance. Am J Infect Control, 2017; 45(10):1101–1105; doi: 10.1016/j.ajic.2017.05.009
21.
MarantidisJ, SussmanRD. Unmet needs in complicated urinary tract infections: Challenges, recommendations, and emerging treatment pathways. Infect Drug Resist, 2023; 16:1391–1405; doi: 10.2147/idr.s382617
22.
CheginiZ, KhoshbayanA, VesalS, et al.Bacteriophage therapy for inhibition of multi drug‐resistant uropathogenic bacteria: A narrative review. Ann Clin Microbiol Antimicrob, 2021; 20(1):30–13; doi: 10.1186/s12941-021-00433-y
23.
LehmanSM, DonlanRM. Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model. Antimicrob Agents Chemother, 2015; 59(2):1127–1137; doi: 10.1128/aac.03786-14
24.
MiloS, HathawayH, NzakizwanayoJ, et al.Prevention of encrustation and blockage of urinary catheters by Proteus mirabilis via pH-triggered release of bacteriophage. J Mater Chem B, 2017; 5(27):5403–5411; doi: 10.1039/c7tb01302g
25.
TownsendE, MoatJ, JamesonE. CAUTI’s next top model—model dependent Klebsiella biofilm inhibition by bacteriophages and antimicrobials. Biofilm, 2020; 2:100038; doi: 10.1016/j.bioflm.2020.100038
26.
El HaddadL, HarbCP, GebaraMA, et al.A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin Infect Dis, 2019; 69(1):167–178; doi: 10.1093/cid/ciy947
27.
BruttinA, BrussowH. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob Agents Chemother, 2005; 49(7):2874–2878; doi: 10.1128/aac.49.7.2874-2878.2005
28.
MeloLD, VeigaP, CercaN, et al.Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections. Front Microbiol, 2016; 7:1024; doi: 10.3389/fmicb.2016.01024
29.
CurtinJJ, DonlanRM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother, 2006; 50(4):1268–1275; doi: 10.1128/aac.50.4.1268-1275.2006
30.
MacCallumN, HowellC, KimP, et al.Liquid-infused silicone as a biofouling-free medical material. ACS Biomater Sci Eng, 2015; 1(1):43–51; doi: 10.1021/ab5000578
31.
RamstedtM, RibeiroIA, BujdakovaH, et al.Evaluating efficacy of antimicrobial and antifouling materials for urinary tract medical devices: Challenges and recommendations. Macromol Biosci, 2019; 19(5):1800384; doi: 10.1002/mabi.201800384
32.
BankevichA, NurkS, AntipovD, et al.SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol, 2012; 19(5):455–477; doi: 10.1089/cmb.2012.0021
TerzianP, Olo NdelaE, GaliezC, et al.PHROG: Families of prokaryotic virus proteins clustered using remote homology. NAR Genom Bioinform, 2021; 3(3):lqab067; doi: 10.1093/nargab/lqab067
35.
CookR, BrownN, RedgwellT, et al.INfrastructure for a PHAge REference database: Identification of large-scale biases in the current collection of cultured phage genomes. Phage (New Rochelle), 2021; 2(4):214–223; doi: 10.1089/phage.2021.0007
36.
OndovBD, TreangenTJ, MelstedP, et al.Mash: Fast genome and metagenome distance estimation using MinHash. Genome Biol, 2016; 17(1):132–114; doi: 10.1186/s13059-016-0997-x
37.
MoraruC, VarsaniA, KropinskiAM. VIRIDIC—A novel tool to calculate the intergenomic similarities of prokaryote-infecting viruses. Viruses, 2020; 12(11):1268; doi: 10.3390/v12111268
38.
TownsendEM, KellyL, GannonL, et al.Isolation and characterization of Klebsiella phages for phage therapy. Phage (New Rochelle), 2021; 2(1):26–42; doi: 10.1089/phage.2020.0046
39.
WrightG, MichniewskiS, JamesonE. DepoRanker: A web tool to predict Klebsiella Depolymerases using machine learning. ArXiv Prepr ArXiv250116405, 2025.
40.
StormsZJ, TeelMR, MercurioK, et al.The virulence index: A metric for quantitative analysis of phage virulence. Phage (New Rochelle), 2020; 1(1):27–36; doi: 10.1089/phage.2019.0001
41.
BlattnerFR, PlunkettG, BlochCA, et al.The complete genome sequence of Escherichia coli K-12. Science, 1997; 277(5331):1453–1462; doi: 10.1126/science.277.5331.1453
42.
AlvesDR, Perez‐EstebanP, KotW, et al.A novel bacteriophage cocktail reduces and disperses P seudomonas aeruginosa biofilms under static and flow conditions. Microb Biotechnol, 2016; 9(1):61–74.
43.
PallavaliRR, DegatiVL, NaralaVR, et al.Lytic bacteriophages against bacterial biofilms formed by multidrug-resistant Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus isolated from burn wounds. Phage (New Rochelle), 2021; 2(3):120–130.
44.
HanlonGW, DenyerSP, OlliffCJ, et al.Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol, 2001; 67(6):2746–2753; doi: 10.1128/AEM.67.6.2746-2753.2001
45.
LebeauxD, GhigoJ-M, BeloinC. Biofilm-related infections: Bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev, 2014; 78(3):510–543.
46.
DoolittleMM, CooneyJJ, CaldwellDE. Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J Ind Microbiol, 1996; 16(6):331–341; doi: 10.1007/BF01570111
47.
HanlonGW. Bacteriophages: An appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents, 2007; 30(2):118–128; doi: 10.1016/j.ijantimicag.2007.04.006
HughesKA, SutherlandIW, ClarkJ, et al.Bacteriophage and associated polysaccharide depolymerases–novel tools for study of bacterial biofilms. J Appl Microbiol, 1998; 85(3):583–590; doi: 10.1046/j.1365-2672.1998.853541.x
50.
HughesKA, SutherlandIW, JonesMV. Biofilm susceptibility to bacteriophage attack: The role of phage-borne polysaccharide depolymerase. Microbiology (Reading), 1998; 144 (Pt 11)(11):3039–3047; doi: 10.1099/00221287-144-11-3039
51.
MatzC. Biofilms as refuge against predation. Lab Chip, 2009; 10:238.
52.
BorinJM, AvraniS, BarrickJE, et al.Coevolutionary phage training leads to greater bacterial suppression and delays the evolution of phage resistance. Proc Natl Acad Sci USA, 2021; 118(23):e2104592118.
53.
MeloL, VieiraM. Physical stability and biological activity of biofilms under turbulent flow and low substrate concentration. Bioprocess Eng, 1999; 20(4):363–368; doi: 10.1007/s004490050604
54.
GandertonL, ChawlaJ, WintersC, et al.Scanning electron microscopy of bacterial biofilms on indwelling bladder catheters. Eur J Clin Microbiol Infect Dis, 1992; 11(9):789–796; doi: 10.1007/bf01960877
55.
TsagkariE, ConnellyS, LiuZ, et al.The role of shear dynamics in biofilm formation. NPJ Biofilms Microbiomes, 2022; 8(1):33; doi: 10.1038/s41522-022-00300-4
56.
KrsmanovicM, BiswasD, AliH, et al.Hydrodynamics and surface properties influence biofilm proliferation. Adv Colloid Interface Sci, 2021; 288:102336.
57.
PaulE, OchoaJC, PechaudY, et al.Effect of shear stress and growth conditions on detachment and physical properties of biofilms. Water Res, 2012; 46(17):5499–5508.
58.
FernandezL, GonzalezS, CampeloAB, et al.Low-level predation by lytic phage phiIPLA-RODI promotes biofilm formation and triggers the stringent response in Staphylococcus aureus. Sci Rep, 2017; 7:40965; doi: 10.1038/srep40965
59.
KellyL, JamesonE. Bacteriophage cocktail shows no toxicity and improves the survival of Galleria mellonella infected with Klebsiella spp. J Virol, 2024; 98(6):e00272-24.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
